by: Darrin Kiessling

10/10/2003

Health officials recently halted a large international study after an early review of the results suggested that the anti-estrogen drug letrozole dramatically reduces the risk of recurrence of cancer among of breast cancer survivors.

About 211,300 new cases of breast cancer are expected to be diagnosed this year in the United States , two-thirds of them in women who have gone through menopause. Most tumors will be estrogen-receptor positive, meaning that the hormone fuels their growth...